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Carotid and Vertebral Artery Transluminal Angioplasty
Study (CAVATAS) study6 demonstrated comparable safety
and efficacy, with a trend toward fewer minor complica-
tions for CAS when compared with surgery. The Leicester
Stopped Trial7 was discontinued by the safety committee
because of an inordinate number of strokes, occurring in
five of the first seven patients who underwent carotid
intervention. This study and its significance have been
questioned because of flawed design, lack of appropriate
safeguards, and the apparent inadequacies in endovascular
skills and experience.8 Several other clinical studies are
underway or in the planning stages, including the large
randomized Carotid Revascularization Endarterectomy
Versus Stent Trial that is likely to provide the most defin-
itive information on the subject. CEA remains the stan-
dard of care at present.
Our clinical experience with endovascular intervention
for treatment of carotid artery disease dates back to April
1994,4 when CAS began to be offered to carefully selected
patients who had been deemed “inoperable” because of
anatomical contraindications to CEA. Procedural strategy
during this initial series included a direct cervical approach
to the common carotid artery (CCA) and the use of bal-
loon-expandable stents. A standardized transfemoral tech-
Carotid angioplasty-stenting (CAS) has been pro-
posed as an alternative to carotid endarterectomy (CEA)
in the treatment of severe stenosis of the internal carotid
artery (ICA).1-3 The procedure is being performed in clin-
ical practice, propelled by the growing view that it may be
an attractive therapeutic option for patients with local
anatomical factors that make CEA difficult or riskier (ie,
restenosis after earlier surgery, “hostile neck” after radical
surgery and/or radiation therapy, and distal ICA
lesions).4,5 It has also been proposed as a treatment
modality competitive with CEA. Two randomized trials
comparing CAS with CEA have been published. The
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Purpose: We tested the clinical applicability, technical results, and morbidity of carotid angioplasty-stenting (CAS) in
the treatment of severe stenosis of the internal carotid artery (ICA) in patients deemed to be high-risk candidates for
carotid endarterectomy (CEA).
Method: After an initial series (1994-1997) of 52 interventions, we adopted the use of a transfemoral access technique
and self-expanding stents in late 1997. From Dec 1, 1997, to Mar 31, 2001, 135 CAS procedures were performed on
132 patients with more than 70% (symptomatic) or more than 80% (asymptomatic) stenoses of the ICA. Sixty percent
of the patients had no symptoms, and 40% of patients had symptoms. The interventional technique was standardized
with the use of a 7F long interventional sheath, balloon pre-dilatation of the stenotic lesion, placement of a self-expand-
ing stent (Wallstent in 12 patients and a SMART stent in 120 patients), and post-balloon dilatation when necessary.
Brain protection devices were not used. Patients were given clopidogrel and aspirin before and after the procedure and
heparin during the intervention.
Results: All procedures except two were completed as planned, with access failure in three patients (2.2%). Residual in-
stent stenosis of less than 20% was detected in 14 of 132 stented vessels (11%) and accepted as a satisfactory angio-
graphic outcome. Neurologic complications included one patient with a single-episode transient ischemic attack (TIA;
motor-sensory deficit of the hand) occurring 2 hours after CAS. One patient sustained a major stroke after thrombo-
sis of the stented ICA, which occurred 3 days after the CAS procedure and 24 hours after open-heart surgery. A third
patient sustained a minor stroke that began intraprocedurally after post-balloon dilatation of the stent, and a fourth
patient had another minor stroke with transient aphasia (beginning during the procedure and resolving after 4 hours)
and monoparesis of the hand, which resolved after 1 week. All stented vessels remained patent during the follow-up
period (range, 2-41 months; mean, 16 ± 9 months), with four instances of hemodynamically significant in-stent
restenosis. Re-intervention with balloon angioplasty was undertaken successfully at 4 months in one patient with
restenosis. The periprocedural mortality rate was 0.
Conclusion: Carotid stenting can be performed with acceptable safety on carefully selected patients by using meticulous,
standardized interventional techniques. It may offer a possibly superior therapeutic alternative for non-CEA candi-
dates. Evolving technological improvements and brain protection devices are likely to enhance its role in the treatment
of carotid artery disease in the future. Surgical endarterectomy remains the standard of care for most patients at the
present time. (J Vasc Surg 2002;35:430-4.)
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nique and self-expanding stents were adopted in
December 1997, when a high-risk protocol for treatment
of “non-CEA candidates” was developed and approved by
the Institutional Review Board (IRB). The purpose of this
report was to review the role of CAS in the treatment of
carotid artery disease during our second-phase clinical
experience by using a standardized transfemoral interven-
tional approach, with emphasis on applicability, technical
results, and neurologic morbidity.
METHODS
Patient population. Between Dec 1, 1997, and Mar
31, 2001, 135 CAS procedures were performed on 132
consecutive patients selected in accordance with a proto-
col that was approved by the IRB to study the feasibility
and safety of CAS on patients deemed (by the vascular
surgery team) to be at high risk for conventional CEA.
During the same period, 191 patients underwent CEA, so
the interventional cohort (N = 132) represents 41% of the
overall patient population undergoing treatment for
carotid artery disease. Every patient signed an informed
consent form that disclosed the investigational nature of
the procedure and its potential risks, especially stroke.
Eighty-six patients were men (65%), and 46 patients were
women (35%), with a mean age of 68 ± 9 years; 11
patients (8%) were 80 years or older. Both symptomatic
(> 70% stenosis) and asymptomatic (> 80% stenosis) ICA
lesions were included in our study group; the former
made up 40% of the group, whereas the latter comprised
60% of the group. Demographics and medical co-mor-
bidities are summarized in Table I. Of the 132 patients
treated with CAS, 92 (69%) were at “anatomical high
risk” for CEA: post-CEA restenosis occurred in 52, distal
ICA lesions (at or above the level of C2) occurred in 22,
and a hostile neck situation occurred in 18. Necks were
considered to be “hostile” in patients with a permanent
tracheostomy, earlier radical neck surgery with resultant
marked deformity, presumed radiation-induced ICA
stenosis, and cases in which the cervical spine was very
stiff and/or unstable, making endotracheal intubation
unsafe or impossible. Forty patients (31%) did not have
any local anatomical contraindication to CEA, but were
found to have severe medical co-morbidities that would
have (presumably) increased the risk of standard opera-
tion; 24 of the patients were classified as class III, and 16
patients were classified as class IV by using Goldman’s
multifactorial index score.9
Diagnosis and patient treatment. Diagnosis of
severe ICA stenosis (as defined) was made by means of
duplex ultrasound scanning and was always confirmed by
means of conventional catheter angiography. The latter
was obtained as a stand-alone diagnostic procedure in 102
patients (77%) or during the initial phase of the CAS pro-
cedure in 30 patients (23%). Patients were examined
before and within 24 hours of CAS by the vascular surgery
team and, in some instances (28 patients, 21%), by an
independent neurologist. Pre-discharge clinical evaluation
and duplex scanning were obtained the morning after the
procedure and then at 30 days, 6 and 12 months, and
yearly thereafter.
Carotid angioplasty-stenting technique. Patients
were given aspirin (325 mg/day) and clopidogrel (Plavix;
75 mg/day) beginning 2 to 3 days before the procedure.
Clopidogrel was continued for 30 days, and aspirin ther-
apy was continued indefinitely. The interventions were
performed in a state-of-the-art (Multi-Star Siemens)
angiosuite, by using local anesthesia at the femoral punc-
ture site supplemented with light intravenous sedation. A
standardized endovascular approach was used, which
included initial femoral entry with a 5F introducer sheath
and power-injector aortic arch angiography in the left
anterior oblique (LAO) projection. Systemic anticoagula-
tion was induced with intravenous heparin, with a target
activated clotting time of 250 to 300 seconds, which was
maintained throughout the intervention. Selective
catheterization of the target vessel was achieved by using a
5F diagnostic catheter (JB1, Uni-select, or JB2) with
advancement of a 0.035-in Glidewire into the appropriate
CCA. The catheter was then passed over the Glidewire to
the distal CCA, to a point just proximal to the bifurcation.
Angiography was used as a means of defining the anatomy
of the external carotid artery (ECA), with subsequent
“anchoring” of a support 0.035-in guidewire (Storq or
Amplatz) in one of its branches. A 7F, 90-cm–long inter-
ventional sheath was introduced from the femoral punc-
ture site to the mid or distal CCA over this guidewire. A
high-quality digital angiogram of the carotid bifurcation
was then obtained by administering radiocontrast through
the sideport of the sheath. A 0.018-in SV-5 Cordis small-
vessel guidewire was used to cross the ICA lesion, which
was then pre-dilated with a 4- by 40-mm Savvy Cordis bal-
loon angioplasty catheter. Stenting involved placement of
a self-expanding device (Wallstent in 12 patients and a
SMART nitinol stent in 120 patients) from the ICA across
the bifurcation into the distal CCA (across the origin of
the ECA). Post-balloon dilatation of the stent involved the
use of a 4.5- by 20-mm or 5- by 20-mm Savvy balloon
catheter. In 26 of the interventions (22%) in which a
SMART stent was used, post-dilatation proved unneces-
sary because of satisfactory angiographic appearance after
stent deployment. Three patients underwent staged bilat-
eral CAS carotid artery interventions; in seven patients,
two (overlapping) stents were used for treatment of the
Table I. Clinical profile of the study group (N = 132)
N %
Men 86 65
Women 46 35
No symptoms (> 80%) 79 60
Symptoms (> 70%) 53 40
Hypertension 92 70
Tobacco abuse 86 65
Diabetes mellitus 49 37
Coronary artery disease 80 60
Hypercholesterolemia 41 31
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carotid artery lesion. On completion of the intervention,
ipsilateral carotid and cerebral angiography (in multiple
views) was obtained as a means of assessing procedural
success and excluding distal embolization. Angiographic
assessment of residual stenosis was determined by using
the North American Symptomatic Carotid Endarter-
ectomy Trial criteria10 of comparing the smallest diameter
at the lesion with a reference diameter of the distal ICA in
a segment with parallel walls. Minimum lumen diameter
was measured by calibrating the imaging system with a
known diameter (sheath or inflated balloon) within the field
of fluoroscopic visualization. Femoral puncture closure
devices were used in 92 (68%) of the interventions: Perclose
(Closer) in 55, VasoSeal in 32, and a Duett device in 5.
RESULTS
Interventional outcome. Three procedures (2.2%)
were considered access failures because of the inability to
catheterize the target aortic arch branch. One of these
patients underwent CEA and recovered uneventfully. The
other two patients were considered to be “inoperable,” one
because of severe cardiac co-morbidity and the other
because of a very distal ICA lesion at the level of C1; nei-
ther patient had a neurologic event during the follow-up
period. Residual in-stent stenosis of less than 20% was iden-
tified by means of completion angiography in 14 of 132
stented carotids (11%) and was accepted as a satisfactory
angiographic outcome. Additionally, in two of 52 interven-
tions for treatment of restenosis (3.8%), the very hard-
fibrotic nature of the lesion precluded full balloon
expansion of the stent, resulting in a residual (persistent)
narrowing of less than 50% with angiography. There were
no instances of vessel wall dissection or rupture, and
patency of the ECA was documented after stenting in every
case except one (0.7%), in which the ECA became
occluded. Post-procedural stent thrombosis occurred in
one patient who underwent coronary artery bypass grafting
48 hours after CAS intervention. Carotid occlusion (and a
major stroke) developed 24 hours after cardiac surgery; this
was the only patient in the series who was not treated with
clopidogrel. All other patients had a patent stented carotid
artery on the pre-discharge duplex scan and also during fol-
low-up (range, 2-41 months; mean, 16 ± 9 months).
Four instances of post-ICA stent restenosis (>50% on
duplex scanning) were identified; only one required re-
intervention (balloon angioplasty), which was performed
4 months after the initial procedure. The two patients with
persistent in-stent narrowing after treatment of restenosis
continued to do well (at 14 and 18 months), without pro-
gression of the less than 50% residual stenosis on serial
duplex scanning.
Neurologic outcome. None of the 102 patients
undergoing diagnostic angiography as a stand-alone pro-
cedure had a neurologic event. Four patients (3%) had
neurologic complications after CAS:
1. One patient sustained a single-episode transient
ischemic attack (TIA), characterized by means of
motor/sensory deficit of the hand, occurring 2 hours
after CAS. He was treated with a 12-hour infusion of
abciximab (ReoPro) and intravenous heparin.
Recovery was complete (by the sixth hour), without
sequelae or recurrences. 
2. A second patient had a major hemispheric stroke
caused by thrombosis of the stented ICA (as afore-
mentioned) occurring 3 days after CAS and 24 hours
after open-heart surgery. This was the only patient in
the series who did not receive clopidogrel therapy
because of the fear of bleeding complications during
and after cardiac surgery.
3. The third patient had a minor stroke that began
intraprocedurally 2 minutes after post-balloon dilata-
tion of the carotid stent with a 5-mm balloon angio-
plasty catheter. The complication resulted in transient
aphasia (lasting several hours) and monoparesis of the
hand, which resolved after 2 weeks.
4. The fourth patient had transient aphasia (beginning at
the end of the procedure and resolving after 4 hours)
and monoparesis of the hand, which resolved com-
pletely after 1 week.
All four patients who sustained a neurologic event had
symptomatic (stroke, TIA) ICA stenoses as the indication
for CAS. Patients 2 and 3 had independent assessment by a
neurologist before and after CAS. There were no deaths,
either periprocedurally or during the follow-up period. Late
strokes were observed in two patients (at 8 and 25 months),
both affecting the cerebral hemisphere supplied by the con-
tralateral (non-stented) carotid artery. One was fatal.
Femoral puncture site complications occurred in five
cases: a large hematoma in three cases, femoral pseudoa-
neurysm in one case, and an arteriovenous fistula in one
case. In all, the diagnosis was confirmed by means of
duplex ultrasound scanning, and none required interven-
tion. Hospitalization was prolonged by 2 days in one
patient with a large hematoma.
DISCUSSION
CEA constitutes one of the best examples of evidence-
based medicine as attested by means of published scientific
proof of efficacy of the operation over best medical man-
agement alone for the treatment of symptomatic and
asymptomatic severe stenoses of the ICA.10-14 However,
patients with serious medical co-morbidities may not fare
as well.15 In addition, local anatomical findings, such as
restenosis after earlier CEA, distal ICA lesions, and
anatomically disadvantaged necks from earlier radical
surgery or radiation therapy, may also constitute impedi-
ments or high-risk factors for CEA. In fact, many, if not
most, practicing vascular surgeons are reluctant to operate
on such patients. Percutaneous CAS has emerged as an
appealing therapeutic alternative in these cases, with the
potential to achieve results equal or possibly superior to
those of CEA in the same clinical setting. With this in
mind, the senior author (F.J.C.) began to offer endovas-
cular intervention to selected patients in 1994.4 This ini-
tial effort involved a direct cervical approach to the carotid
artery and the use of balloon-expandable stents. Such ini-
tial experience demonstrated the feasibility of the
approach, but also showed significant shortcomings
related to the technique of carotid artery puncture in the
neck. It limited interventional capabilities and was accom-
panied by serious threats of hemorrhagic complications at
the puncture site from difficulties with external compres-
sion. The transfemoral approach constitutes, clearly, a
more optimal access strategy, as does the use of self-
expanding stents, which were adopted in late 1997.
Refinements of technique led to a standardized approach,
with critical assessment of angiographic arch anatomy and
careful avoidance of CAS intervention in the face of unfa-
vorable findings (Table II). The latter relate mainly to aor-
tic arch and carotid artery anatomy and ICA lesion
characteristics such as length, degree of calcification, and
the possibility of associated clot or other intraluminal
defects on angiography. These factors have been reported
anecdotally to be associated with an increased risk of com-
plications during CAS.
The potential for cerebral embolization and stroke are
major concerns with catheter interventions in the cere-
brovascular territory. Carotid artery plaques have been
shown to release particles during transluminal manipula-
tion.16 It is surprising that stroke does not occur more fre-
quently after CAS and that the procedure can be
performed relatively safely, without protection, on care-
fully selected patients. Such “low incidence” of stroke is
likely related to a number of factors, including brain toler-
ance to emboli, under-diagnosis of lesser neuropsycho-
logic changes that may go undetected, and the failure to
evaluate patients with time.17 It could be argued that our
neurologic complication rate (as reported) does not reflect
all events because only a minority of patients (21%) under-
went independent, systematic assessment by a neurologist.
This may well be the case, but it would be difficult to
understand how a major stroke could be missed in patients
who were cared for by several physicians and nurses dur-
ing the hospital stay. Brain protection technologies, cur-
rently being rapidly developed, will offer exciting new
possibilities that are likely to enhance safety and promise
to add considerable credibility to a procedure, the appro-
priateness of which continues to be considered suspect by
many, if not most, vascular surgeons.18,19 They were not
available for use during the period of the experience
reported. The single major stroke in our experience was
not related to embolization, but instead to stent throm-
bosis occurring after open-heart surgery in a patient who
was not on clopidogrel antiplatelet therapy. There is con-
sensus among leading carotid interventionists that this
form of therapy is (probably) critically important, but it is
an opinion without scientific validation at this time.
Abciximab was used in only one patient for treatment of a
TIA episode occurring 2 hours after CAS; we continue to
reserve its use for such “rescue” indication only.
Careful case selection, impeccable technical execution,
and “knowing when to quit” are some of the most impor-
tant aspects of enhancing safety with CAS intervention.
Restenotic carotid lesions have low embolic potential and
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are probably the safest to dilate and stent without protec-
tion.20,21 They should be looked on as the obvious indi-
cation target for beginner carotid interventionists.
Restenoses, distal ICA lesions, and hostile neck situations
should, in our view (and that of other authors20), continue
to be the prime indications for CAS currently. Expanding
the indications to include “all comers” cannot be justified
outside the setting of a controlled US Food and Drug
Administration-sponsored clinical trial. Data in support of
such an aggressive attitude are not likely to be forthcom-
ing for several years, and, in the end, CAS may well be
found to be a reasonable and possibly superior treatment
alternative for non-CEA candidates only.
In conclusion, we have found CAS to be a valuable
addition to our armamentarium. It is reserved largely for
patients who are not ideal candidates for CEA. Further
expansion of clinical indications is not yet recommended
and should await further information on durability and effi-
cacy to be generated by current and future clinical trials.
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